Imunon, Inc. Increase (Decrease) in Accrued Investment Income Receivable
Imunon, Inc. (IMNN) reported Increase (Decrease) in Accrued Investment Income Receivable of -$68.14 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedInvestmentIncomeReceivable · last filed 2025-02-27
- Imunon, Inc. increase (decrease) in accrued investment income receivable for the quarter ending 2023-12-31 was -$36.31K, a 136.88% decline year-over-year.
- Imunon, Inc. increase (decrease) in accrued investment income receivable for the quarter ending 2023-09-30 was $16.61K, a 2066.10% increase year-over-year.
- Imunon, Inc. increase (decrease) in accrued investment income receivable for the quarter ending 2023-06-30 was -$35.87K, a 354.69% decline year-over-year.
- Imunon, Inc. increase (decrease) in accrued investment income receivable for the quarter ending 2023-03-31 was -$12.58K.
- Imunon, Inc. increase (decrease) in accrued investment income receivable for fiscal 2023 was -$68.14K, a 439.19% decline from fiscal 2022.
- Imunon, Inc. increase (decrease) in accrued investment income receivable for fiscal 2022 was $20.09K, a 81.54% decline from fiscal 2021.
- Imunon, Inc. increase (decrease) in accrued investment income receivable for fiscal 2021 was $108.84K.
- Imunon, Inc. increase (decrease) in accrued investment income receivable for fiscal 2020 was -$21.37K.
| Period end | Increase (Decrease) in Accrued Investment Income Receivable 3 month | Increase (Decrease) in Accrued Investment Income Receivable 6 month | Increase (Decrease) in Accrued Investment Income Receivable 9 month | Increase (Decrease) in Accrued Investment Income Receivable 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$36.31K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$19.69K derived: sum of 2 quarters · filed 2025-02-27 | -$55.56K derived: sum of 3 quarters · filed 2025-02-27 | -$68.14K 10-K · filed 2025-02-27 |
| 2023-09-30 | $16.61K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$19.25K derived: sum of 2 quarters · filed 2024-11-07 | -$31.83K 10-Q · filed 2024-11-07 | $66.61K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$35.87K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$48.44K 10-Q · filed 2024-08-14 | $49.99K derived: sum of 3 quarters · filed 2024-08-14 | $50.76K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$12.58K 10-Q · filed 2024-05-13 | $85.86K derived: sum of 2 quarters · filed 2024-05-13 | $86.63K derived: sum of 3 quarters · filed 2024-05-13 | $100.71K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $98.44K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $99.20K derived: sum of 2 quarters · filed 2024-03-28 | $113.29K derived: sum of 3 quarters · filed 2024-03-28 | $20.09K 10-K · filed 2024-03-28 |
| 2022-09-30 | $767.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $14.85K derived: sum of 2 quarters · filed 2023-11-14 | -$78.35K 10-Q · filed 2023-11-14 | -$7.91K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $14.08K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$79.12K 10-Q · filed 2023-08-10 | -$8.68K derived: sum of 3 quarters · filed 2023-08-10 | -$75.27K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$93.20K 10-Q · filed 2023-05-11 | -$22.76K derived: sum of 2 quarters · filed 2023-05-11 | -$89.35K derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | $70.44K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $3.84K derived: sum of 2 quarters · filed 2023-03-30 | $108.84K 10-K · filed 2023-03-30 | |
| 2021-09-30 | -$66.60K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $38.40K 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $105.00K 10-Q · filed 2022-08-15 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$7.87K derived: sum of 2 quarters · filed 2022-03-31 | -$22.71K derived: sum of 3 quarters · filed 2022-03-31 | -$21.37K 10-K · filed 2022-03-31 |
| 2020-09-30 | -$7.87K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$22.71K derived: sum of 2 quarters · filed 2021-11-15 | -$21.37K 10-Q · filed 2021-11-15 | -$26.97K derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | -$14.85K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$13.50K 10-Q · filed 2021-08-12 | -$19.11K derived: sum of 3 quarters · filed 2021-08-12 | -$57.81K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $1.34K 10-Q · filed 2021-05-14 | -$4.26K derived: sum of 2 quarters · filed 2021-05-14 | -$42.96K derived: sum of 3 quarters · filed 2021-05-14 | -$55.36K derived: sum of 4 quarters · filed 2021-05-14 |
| 2019-12-31 | -$5.60K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | -$44.30K derived: sum of 2 quarters · filed 2021-03-19 | -$56.70K derived: sum of 3 quarters · filed 2021-03-19 | -$46.94K 10-K · filed 2021-03-19 |
| 2019-09-30 | -$38.70K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | -$51.10K derived: sum of 2 quarters · filed 2020-11-16 | -$41.34K 10-Q · filed 2020-11-16 | -$49.77K derived: sum of 4 quarters · filed 2020-11-16 |
| 2019-06-30 | -$12.40K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | -$2.64K 10-Q · filed 2020-08-14 | -$11.07K derived: sum of 3 quarters · filed 2020-08-14 | $8.84K derived: sum of 4 quarters · filed 2020-08-14 |
| 2019-03-31 | $9.76K 10-Q · filed 2020-05-15 | $1.32K derived: sum of 2 quarters · filed 2020-05-15 | $21.24K derived: sum of 3 quarters · filed 2020-05-15 | |
| 2018-12-31 | -$8.44K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | $11.48K derived: sum of 2 quarters · filed 2020-03-25 | $13.87K 10-K · filed 2020-03-25 | |
| 2018-09-30 | $19.91K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $22.31K 10-Q · filed 2019-11-14 | ||
| 2018-06-30 | $2.39K 10-Q · filed 2019-08-14 | |||
| 2017-12-31 | $50.43K 10-K · filed 2018-03-27 | |||
| 2016-12-31 | -$22.72K 10-K · filed 2018-03-27 | |||
| 2015-12-31 | -$183.30K 10-K · filed 2017-03-24 | |||
| 2014-12-31 | -$2.02K 10-K · filed 2016-03-30 | |||
| 2013-12-31 | $146.12K 10-K · filed 2016-03-30 | |||
| 2013-06-30 | -$27.43K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | $166.67K 10-Q · filed 2013-08-08 | -$21.05K derived: sum of 3 quarters · filed 2015-03-12 | $34.51K derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-03-31 | $194.10K 10-Q · filed 2013-05-09 | $6.38K derived: sum of 2 quarters · filed 2015-03-12 | $61.94K derived: sum of 3 quarters · filed 2015-03-12 | -$200.65K derived: sum of 4 quarters · filed 2015-03-12 |
| 2012-12-31 | -$187.72K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | -$132.16K derived: sum of 2 quarters · filed 2015-03-12 | -$394.75K derived: sum of 3 quarters · filed 2015-03-12 | -$177.82K 10-K · filed 2015-03-12 |
| 2012-09-30 | $55.56K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | -$207.04K derived: sum of 2 quarters · filed 2013-08-08 | $9.90K 10-Q · filed 2012-11-09 | |
| 2012-06-30 | -$262.60K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | -$45.66K 10-Q · filed 2013-08-08 | ||
| 2012-03-31 | $216.93K 10-Q · filed 2013-05-09 | |||
| 2011-09-30 | -$259.67K 10-Q · filed 2012-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |